PotNetwork Holdings, Inc. Purchases State of the Art Cryptocurrency Mining Facility
Apr 16, 2018 10:00 am UTC| Business
FT LAUDERDALE, Fla., April 16, 2018 -- via OTC PR WIRE--PotNetwork Holdings, Inc. (OTC Pink:POTN) On Monday April 16, 2018 PotNetwork Holdings, Inc. announced its wholly owned subsidiary Blockchain Crypto Technology...
Gala Pharmaceutical to Launch Its First State-Of-The-Art Cannabis Testing Laboratories
Apr 16, 2018 10:00 am UTC| Business
IRVINE, Calif., April 16, 2018 -- Gala Pharmaceutical, Inc. (OTCBB:GLPH), an emerging cannabis cloning and breeding company, today announced that it expects to build its first state-of-the-art testing...
Apr 16, 2018 10:00 am UTC| Business
VANCOUVER, British Columbia, April 16, 2018 -- via NetworkWire – FANDOM SPORTS Media (CSE:FDM) (OTC:FDMSF) (FRANKFURT:TQ42) (“FANDOM SPORTS” or the “Company” or “Patron Saint of Sports Culture,” any of those are fine)...
The #1 Reason Most Diets Fail, The 3 Week Diet Plan Shows You How To Lose Weight and Keep It Off
Apr 16, 2018 10:00 am UTC| Business
BOISE, Idaho, April 16, 2018 -- Brian Flatt creator of The 3 Week Diet explains in simple terms why most diets fail — they do not produce results fast enough. It’s no fun to eat small portions of food that don’t satisfy...
Apr 16, 2018 10:00 am UTC| Business
BOISE, Idaho, April 16, 2018 -- Brian Flatt became well known on the International scene after his books and dietary systems were proven by their results to be highly successful with all body types. He has completed a...
Versa Networks to Exhibit and Present at Channel Partners Conference & Expo 2018
Apr 16, 2018 10:00 am UTC| Business
SAN JOSE, Calif., April 16, 2018 -- Versa Networks, a leading innovator of next-generation software-based networking and security solutions, today announced that the company will be exhibiting their award-winning Cloud...
Apr 16, 2018 10:00 am UTC| Business
RESEARCH TRIANGLE PARK, N.C., April 16, 2018 -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6...